Login to Your Account



Clinic Roundup


Tuesday, June 26, 2012

• Generex Biotechnology Corp., of Worcester, Mass., said its Indian licensee, Shreya Life Sciences Pvt. Ltd., of Mumbai, plans to complete the Phase III study of Oral-lyn, Generex' proprietary buccal insulin spray product, in India by the end of July and begin statistical data analysis. To date, 125 patients at 14 sites have completed the Phase III study of Oral-lyn, branded in India as Recosulin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription